Aligos therapeutics to announce topline results from the phase 2a herald study of alg-055009 for the treatment of mash on september 19, 2024

South san francisco, calif., sept. 18, 2024 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs, “aligos”, “company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the company will share the topline results from the phase 2a herald study of alg-055009, a thyroid hormone receptor beta (thr-Β) agonist, in metabolic-dysfunction associated steatohepatitis (mash) subjects on thursday, september 19, 2024 prior to the market open. following the announcement, the company will host a conference call and webcast at 8:30am et/5:30am pt.
ALGS Ratings Summary
ALGS Quant Ranking